New York – September 21, 2016 – Cooley advised AveXis and a selling stockholder on their recent $168.9 million primary/secondary offering of an aggregate of 4,887,500 shares of common stock.
AveXis, which trades on The NASDAQ Global Select Market, is a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases.
Cooley also advised AveXis on its IPO earlier this year.
About Cooley LLP
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.
Cooley has 900 lawyers across 12 offices in the United States, China and Europe.